Balanced Portfolio Recommendation: Switch 5% Allocation BBUS to QUS
You are unauthorized to view this page. Username Password Remember Me Forgot Password
You are unauthorized to view this page. Username Password Remember Me Forgot Password
You are unauthorized to view this page.
We recommend reallocating 2% of our portfolio from Elders (ELD) to Nufarm (GNC). This decision is based on the realization of a 9.2% profit in Elders and the assessment that Nufarm is currently undervalued, as supported by its recent earnings report and market conditions.
Overall, Challenger’s financial results for FY2024 appear to have exceeded market expectations, particularly in terms of profitability and EPS growth, despite slightly lower total Life sales. The company’s performance has been recognized by an increased dividend and a positive outlook from most analysts.
ResMed Inc.(RMD) pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. and lower costs for consumers and healthcare systems in more than 140 countries.
ADD to Challenger (CGF) into Earnings on the 13th August
Balanced Portfolio – SELL 5% Resmed (RMD) Take +10% profit
We recommended buying ResMed Inc. (RMD) due to its potential for strong performance in the upcoming earnings season on the 29th of July
A minor equities panic has started to spread across global markets in the last few sessions as investors grow increasingly concerned that the US economy will go into recession.
To reassure you, the MPC Markets Balanced Portfolio is defensively positioned and while we are still not immune to the broader market weakness, we have been wary a move like this could happen
We advise selling 4% of our portfolio allocation in Woolworths Group Ltd (WOW). The stock has provided an 11% profit, rising from our entry at $30.8 to an exit at $34.2. Given the recent challenges faced by the company, including operational issues and potential management changes, there is uncertainty surrounding the upcoming earnings release. These factors could lead to a revaluation of the stock, making it a prudent time to lock in profits and reduce exposure.
Poor economic data out of the US has started to pile up along with soured sentiment on the Mega-Cap stocks and the AI thematic. We are recommending a 5% allocation to a portfolio protection tool or “short hedge” to buffer the damage from any downside move
ResMed Inc.(RMD) pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. and lower costs for consumers and healthcare systems in more than 140 countries.